Hypofractionated thyroid carcinoma is a type of thyroid malignancy between differentiated thyroid carcinoma and undifferentiated carcinoma. Its cytological origin is thyroid follicular epithelial cells, and its prognosis is worse than that of differentiated subfamily carcinoma, but better than that of undifferentiated carcinoma. Currently, the pathological definition of hypofractionated thyroid cancer is not uniform, but the following conditions are usually required to confirm the diagnosis: 1. solid, beam-like or island-like growth pattern; 2. lack of common nuclear features of papillary carcinoma; 3. at least one of the three features of coiled nuclei, more than 3 nuclear schizograms per 10 high-powered views or necrosis. Hypofractionated thyroid cancer is more aggressive compared to differentiated thyroid cancer. The following factors are usually considered to adversely affect the prognosis of patients: age over 45 years, tumor size over 4 cm, no iodine uptake, cervical lymph node involvement, tumor necrosis, more than 3 nuclear schizograms per 10 high-powered views, and local recurrence or distant metastasis. Clinical treatment for hypofractionated thyroid cancer is mainly surgery, and usually requires adjuvant iodine-131 therapy after surgery. Radiotherapy, chemotherapy and molecular targeted therapy can also be considered, but the efficacy needs to be confirmed by further studies.